Vestal Point Capital, LP

Entity
Company
Business address
632 Broadway, Suite 602, 10012 New York, NY
Phone
6469894000
State of incorporation
DE
Fiscal year end
December 31
13F signature
Ilko Menkov - Partner, COO and CCO
13D/G Schedule signature
Vestal Point Capital, LP - By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
All SEC filings
View on sec.gov
⭐ Add to watchlist ⭐
Vestal Point Capital, LP has filed 46 SEC EDGAR filings since 2/13/2024

Latest Filings

Form type Document Filing Description Filing date Reporting date File number(s)
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
SCHEDULE 13G Open Document Open Filing Nov 14, 2025
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
SCHEDULE 13G Open Document Open Filing Nov 14, 2025
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
13F-HR Open Document Open Filing Nov 14, 2025 Sep 30, 2025 028-23784
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
SCHEDULE 13G/A Open Document Open Filing Nov 14, 2025
N-PX Open Document Open Filing Aug 27, 2025 Jun 30, 2025 028-23784
SCHEDULE 13G/A Open Document Open Filing Aug 14, 2025
13F-HR Open Document Open Filing Aug 14, 2025 Jun 30, 2025 028-23784
SCHEDULE 13G/A Open Document Open Filing Aug 14, 2025
SCHEDULE 13G/A Open Document Open Filing Aug 14, 2025
SCHEDULE 13G Open Document Open Filing Aug 14, 2025
SCHEDULE 13G/A Open Document Open Filing Aug 14, 2025
13F-HR Open Document Open Filing May 15, 2025 Mar 31, 2025 028-23784
SCHEDULE 13G Open Document Open Filing May 15, 2025
SCHEDULE 13G Open Document Open Filing May 15, 2025
SCHEDULE 13G Open Document Open Filing May 15, 2025
SCHEDULE 13G/A Open Document Open Filing May 15, 2025
SCHEDULE 13G/A Open Document Open Filing May 15, 2025
SCHEDULE 13G/A Open Document Open Filing May 15, 2025
13F-HR Open Document Open Filing Feb 14, 2025 Dec 31, 2024 028-23784
SCHEDULE 13G Open Document Open Filing Feb 14, 2025
SCHEDULE 13G/A Open Document Open Filing Feb 14, 2025
SCHEDULE 13G Open Document Open Filing Feb 14, 2025
SCHEDULE 13G Open Document Open Filing Feb 14, 2025
SCHEDULE 13G Open Document Open Filing Feb 14, 2025
13F-HR Open Document Open Filing Nov 14, 2024 Sep 30, 2024 028-23784
SC 13G Open Document Open Filing ASTRIA THERAPEUTICS, INC. Nov 14, 2024
SC 13G Open Document Open Filing PASSAGE BIO, INC. Nov 14, 2024
SC 13G Open Document Open Filing SOLID BIOSCIENCES INC. Nov 14, 2024
SC 13G Open Document Open Filing KALVISTA PHARMACEUTICALS, INC. Nov 14, 2024
SC 13G Open Document Open Filing BLACK DIAMOND THERAPEUTICS, INC. Nov 14, 2024
SC 13G/A Open Document Open Filing Nov 14, 2024
SC 13G/A Open Document Open Filing LYRA THERAPEUTICS, INC. Nov 14, 2024
SC 13G/A Open Document Open Filing APPLIED THERAPEUTICS, INC. Nov 14, 2024
N-PX Open Document Open Filing Aug 29, 2024 Jun 30, 2024 028-23784
13F-HR Open Document Open Filing Aug 14, 2024 Jun 30, 2024 028-23784
13F-HR Open Document Open Filing May 14, 2024 Mar 31, 2024 028-23784
SC 13G Open Document Open Filing APPLIED THERAPEUTICS, INC. Feb 13, 2024
SC 13G Open Document Open Filing LYRA THERAPEUTICS, INC. Feb 13, 2024
SC 13G Open Document Open Filing UNIQURE N.V. Feb 13, 2024
13F-HR Open Document Open Filing Feb 13, 2024 Dec 31, 2023 028-23784